The Indianapolis-based drugmaker is working with financial advisers to gauge buyer interest in a portfolio of older, off-patent drugs. The portfolio is valued around $200 million to $300 million.
Potential buyers may include other pharmaceutical companies with a presence in Asia.
Following in the steps of other drugmakers, Eli Lilly has been trimming its portfolio of older drugs in an effort to refocus on more profitable areas, such as oncology.
Read the full report here.
More articles on pharmacy:
Florida adds CVS, Walgreens to opioid lawsuit
Pfizer to hike price of 41 drugs in January
Bristol-Myers Squibb to lay off 69 employees in Florida
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
